In NSCLC, switching to PD-L1 inhibitor therapy after progression on PD-1 inhibitor therapy still results in disease control rate (DCR) of more than 30% and PFS can be extended by about 3 or 4 months (47–49); patient benefit has also been reported in triple-negative breast cancer (50). Here, CD274 is linked to non-small cell lung carcinoma.